News

The therapy, which has been studied in various Phase I and II clinical trials, demonstrated the potential to amplify T cells across the subsets, improve the immune system,

Orion Biotechnology Canada is a drug discovery company targeting earlier undruggable GPCRs. A biotech firm, Peptilogics is into engineering peptide therapeutics by bringing together computation and biology to

New investors Sands Capital and Vivo Capital have jointly led the financing round, which has also seen participation from new investor Dreavent 6. Sofinnova Partners, New York City

The company is a joint venture between WuXi Biologics and WuXi STA and provides end-to-end contract research, development, and manufacturing of bioconjugates, such as ADCs. Under the terms

The new highly selective, fully human monoclonal antibody, abelacimab has been designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. It shows dual inhibitory activity against both

These therapies will be developed using Ryvu’s stimulator of interferon genes (STING) technology. The deal expands Exelixis’ biotherapeutics portfolio by combining its tumour-specific targeting approaches with the Ryvu’s

The latest move follows a strategic multi-year research collaboration of the entities for pre-clinical development of investigational TIL therapies in November last year. Under the expanded collaboration, Turnstone

An investigational anti-amyloid beta (Aβ) protofibril antibody, lecanemab is developed as part of a strategic research alliance between Eisai and BioArctic. It selectively binds to neutralise and eliminate

Mogrify has developed a suite of platform technologies that use a systematic big-data approach for direct cellular reprogramming and to maintain cell identity. Its epiMOGRIFY and MOGRIFY platforms